Shares of Moderna Inc. (MRNA) are climbing a bit on Tuesday, and here's why: Europe just gave the thumbs-up to a vaccine that's like getting two birds with one stone. The European Commission approved mCOMBRIAX, which is the world's first combo shot for flu and COVID-19. Think of it as simplifying your annual vaccine routine—instead of two jabs, you might just need one, at least if you're 50 or older.
This isn't just a regulatory checkbox; it's a pretty big deal for Moderna. mCOMBRIAX is now the company's fourth authorized product, which shows they're moving beyond being just a COVID-19 player. The approval is based on solid numbers from a Phase 3 trial called mRNA-1083, which involved about 4,000 adults split into two age groups. The data showed that after a single dose, the vaccine triggered a stronger immune response against three flu strains and the SARS-CoV-2 virus compared to giving the licensed flu and COVID vaccines separately. All the main goals for proving it works as well or better were met. There was one hiccup: in adults 65 and up, it didn't show a statistically higher response against the B/Yamagata flu strain, but that strain isn't even recommended for seasonal shots anymore, so it's kind of a moot point.
This news comes at an interesting time for Moderna. Back in March, the company wrapped up some legal drama by settling with Arbutus Biopharma Corporation (ABUS) and Roivant Inc.'s (ROIV) Genevant Sciences. They agreed to pay a lump sum of $950 million in the third quarter to resolve all patent lawsuits related to their COVID-19 vaccine, Spikevax, and another product called mRESVIA. That settlement basically clears the deck, letting Moderna focus on growth without that legal cloud hanging over it.
And there's more in the pipeline. Moderna's investigational flu vaccine, mRNA-1010, is currently being reviewed by the FDA, with a decision date set for August 5. If approved, it would target the same older adult group, giving the company another potential revenue stream. So, while today's approval is about a combo shot, it's part of a bigger picture where Moderna is building out its vaccine business piece by piece.
As for the stock, Moderna shares were up 0.36% at $54.78 when this was published. It's not a huge jump, but in the world of biotech, every regulatory win counts, especially when it involves a first-of-its-kind product that could make life easier for millions of people.
.jpeg)
